Withdrawing heart failure meds, the best DOAC for octogenarians, and more
Dec 07, 2018•8 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week, apixaban edges out other DOACs for octogenarians, methotrexate fails to cut cardiovascular events in a large trial,
withdrawing heart failure medications after recovery leads to relapse,
and showing patients their own atherosclerosis may reduce their cardiovascular event risk.
For the best experience, listen in Metacast app for iOS or Android